Photocure Total Liabilities
Photocure total liabilities. Based on the latest financial reports, Photocure (PHO) has total liabilities worth Nkr294.67 Million NOK (≈ $31.01 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Photocure (PHO) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Photocure (2000–2025)
Total liabilities of Photocure from 2000 to 2025. This chart illustrates how Photocure's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Photocure to evaluate the company's liquid asset resilience ratio.
Photocure Competitors by Total Liabilities
The table below lists competitors of Photocure ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Forrester Research Inc
NASDAQ:FORR
|
USA | $303.01 Million |
|
Lan Fa Textile Co Ltd
TW:1459
|
Taiwan | NT$2.12 Billion |
|
Rawlplug S.A.
WAR:RWL
|
Poland | zł836.68 Million |
|
Varia US Properties Ltd
SW:VARN
|
Switzerland | CHF656.47 Million |
|
Bank Artha Graha Internasional
JK:INPC
|
Indonesia | Rp28.83 Trillion |
|
Bukaka Teknik Utama Tbk Pt
JK:BUKK
|
Indonesia | Rp16.61 Trillion |
|
Fate Therapeutics Inc
NASDAQ:FATE
|
USA | $109.61 Million |
|
Astec LifeSciences Limited
NSE:ASTEC
|
India | Rs4.69 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Photocure's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Photocure.
Liquidity & Leverage Metrics
Photocure Total Liabilities Ratios Explained
Photocure total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Photocure's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Photocure (2000–2025)
The table below shows the annual total liabilities of Photocure from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Nkr222.83 Million ≈ $23.45 Million |
-6.13% |
| 2024-12-31 | Nkr237.37 Million ≈ $24.98 Million |
+3.60% |
| 2023-12-31 | Nkr229.12 Million ≈ $24.11 Million |
-10.60% |
| 2022-12-31 | Nkr256.30 Million ≈ $26.97 Million |
-10.70% |
| 2021-12-31 | Nkr287.01 Million ≈ $30.20 Million |
+7.13% |
| 2020-12-31 | Nkr267.92 Million ≈ $28.19 Million |
+449.43% |
| 2019-12-31 | Nkr48.76 Million ≈ $5.13 Million |
-11.10% |
| 2018-12-31 | Nkr54.85 Million ≈ $5.77 Million |
+21.84% |
| 2017-12-31 | Nkr45.02 Million ≈ $4.74 Million |
+32.77% |
| 2016-12-31 | Nkr33.91 Million ≈ $3.57 Million |
-10.76% |
| 2015-12-31 | Nkr38.00 Million ≈ $4.00 Million |
+24.50% |
| 2014-12-31 | Nkr30.52 Million ≈ $3.21 Million |
-6.39% |
| 2013-12-31 | Nkr32.60 Million ≈ $3.43 Million |
-38.15% |
| 2012-12-31 | Nkr52.71 Million ≈ $5.55 Million |
-24.53% |
| 2011-12-31 | Nkr69.85 Million ≈ $7.35 Million |
+27.02% |
| 2010-12-31 | Nkr54.99 Million ≈ $5.79 Million |
+33.86% |
| 2009-12-31 | Nkr41.08 Million ≈ $4.32 Million |
+7.67% |
| 2008-12-31 | Nkr38.15 Million ≈ $4.01 Million |
-7.85% |
| 2007-12-31 | Nkr41.40 Million ≈ $4.36 Million |
-14.62% |
| 2006-12-31 | Nkr48.49 Million ≈ $5.10 Million |
-15.29% |
| 2005-12-31 | Nkr57.24 Million ≈ $6.02 Million |
-35.06% |
| 2004-12-31 | Nkr88.14 Million ≈ $9.28 Million |
-13.16% |
| 2003-12-31 | Nkr101.50 Million ≈ $10.68 Million |
-23.11% |
| 2002-12-31 | Nkr132.01 Million ≈ $13.89 Million |
+119.39% |
| 2001-12-31 | Nkr60.17 Million ≈ $6.33 Million |
+26.70% |
| 2000-12-31 | Nkr47.49 Million ≈ $5.00 Million |
-- |
About Photocure
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination pro… Read more